New medicines
Tarceva
Composition: Erlotinib.
Presentation: Film-coated tablet.
Class: tyrosine kinase inhibitor.
Indications: Treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Dosage: 150mg daily taken at least one hour before or two hours after food. When dose adjustment is necessary, reduce in 50mg steps.
Precautions: Use in patients with severe hepatic impairment or severe renal impairment is not recommended. Use in children is not recommended. Concomitant treatment with CYP3A4 inducers and inhibitors should be avoided. Smokers should be advised to stop smoking since plasma concentration of erlotinib could be reduced. Interstitial lung disease has been reported uncommonly and patients who develop acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnoea, cough or fever should be evaluated for interstitial lung disease. Caution should be exercised when using antacids, proton pump inhibitors and H2 antagonists with erlotinib.
Side effects: Very common (>1/10) infection, anorexia, conjunctivitis, keratoconjunctivitis sicca, dyspnoea, cough, diarrhoea, nausea, vomiting, stomatatis, abdominal pain, rash, pruritis, dry skin, fatigue. Common (>1/100) gastrointestinal bleeding, liver function test abnormalities, keratitis.
Legal category: POM
Net price: 30 x 150mg £1,631.53, 30 x 100mg £1,324.14.
Contact details: Roche, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY. Telephone 0800 328 1629.
Apidra
Composition: Insulin glulisine.
Presentation: Solution for injection containing 100U insulin glulisine per ml.
Class: Human insulin analogue.
Indications: Treatment of adult patients with diabetes mellitus.
Dosage: Given shortly before (0–15 mins) or soon after meals. Apidra should be used with an intermediate or long acting insulin or basal insulin analogue and can be used with oral hypoglycaemics. Dosage should be adjusted according to individual requirements.
Apidra can be given by subcutaneous injection or by continuous subcutaneous pump infusion.
Precautions: Medical supervision and monitoring recommended when transferring from other insulins.
Side effects: Hypoglycaemia, injection site reactions and local hypersensitivity.
Legal category: POM.
Net price: 10ml vial £17.27, 5 x 3ml cartridges £29.45.
Contact details: Aventis Pharma, 1 Onslow Street, Guildford, Surrey GU1 4YS. Telephone 01483 505515.
Prescription Products
BuTrans
BuTrans (buprenorphine) transdermal patches are now available from Napp. They are licensed for the treatment of severe opioid-responsive pain conditions, which are not adequately responding to non-opioid analgesics. There are three patch strengths available, delivering 5µg/hour, 10µg/hour and 20µg/hour. The patches should be changed every seventh day. Net price 5µg/hour, 2 patches £9, 10µg/hour, 4 patches £32.72, 20µg/hour, 4 patches £59.59. Legal category: POM CD (schedule 3).
Back to Top |